Questions over DANBIO relevance for non-medical switching

Posted 22/02/2019

Italian rheumatologists Fabrizio Cantini and Maurizio Benucci commented on the paper from Glintborg and co-authors ‘To switch or not to switch’, which report...

EC approval for pegfilgrastim biosimilar Fulphila Biosimilars/News | Posted 22/02/2019
UK pharmacists gain powers to address drug shor... Policies & Legislation | Posted 22/02/2019
Biosimilar teriparatide approved for the treatm... Biosimilars/Research | Posted 22/02/2019
Sandoz makes biological deal in China Pharma News | Posted 22/02/2019
Three FDA approvals for Glenmark as it enters U... Biosimilars/News | Posted 22/02/2019
Safety surveillance of bevacizumab biosimilar (... Generics/Research | Posted 15/02/2019
PanGen gains Malaysian approval for epoetin alf... Biosimilars/News | Posted 15/02/2019
European regulatory framework for approval of b... Generics/Research | Posted 15/02/2019
45 US states have passed biosimilar substitutio... Policies & Legislation | Posted 15/02/2019
Impact of generic reference pricing on candesar... Generics/Research | Posted 15/02/2019
Zydus gets FDA approval for skin, heart and aci... Generics/News | Posted 15/02/2019
Long-term stability of trastuzumab biosimilar u... Biosimilars/Research | Posted 08/02/2019
EMA approval for adalimumab biosimilars Idacio... Biosimilars/News | Posted 08/02/2019
Barriers and facilitators to biosimilar prescri... Biosimilars/Research | Posted 08/02/2019
Australia’s PBAC recommends substitution of ada... Biosimilars/News | Posted 08/02/2019
India tightens regulation on generics manufactu... Policies & Legislation | Posted 08/02/2019
Fuji Pharma acquires stake in Alvotech Pharma News | Posted 08/02/2019
Australia’s TGA will keep same names for biolog... Policies & Legislation | Posted 01/02/2019
Tanvex BioPharma submits filgrastim biosimilar... Biosimilars/News | Posted 01/02/2019
Liability chain of biosimilar switching Biosimilars/Research | Posted 01/02/2019
Generics applications under review by EMA – Jan... Generics/General | Posted 01/02/2019
FDA approves trastuzumab biosimilar Herzuma Biosimilars/News | Posted 01/02/2019
Adalimumab biosimilar Imraldi makes waves in Eu... Biosimilars/General | Posted 01/02/2019
Teva receives FDA approval for Sabril and launc... Generics/News | Posted 01/02/2019
Biosimilars - to switch or not to switch Biosimilars/Research | Posted 25/01/2019
FDA approves trastuzumab biosimilar Ontruzant Biosimilars/News | Posted 25/01/2019
Biosimilars applications under review by EMA –... Biosimilars/General | Posted 25/01/2019
Non-profit generics maker expects first generic... Generics/General | Posted 25/01/2019
Sun Pharma gets FDA approval for ganirelix acet... Generics/News | Posted 25/01/2019
Positive phase III results for rituximab biosim... Biosimilars/Research | Posted 25/01/2019
Glenmark makes deal for ophthalmic generics Pharma News | Posted 25/01/2019
Top 10 most read GaBI Online articles in 2018 Pharma News | Posted 18/01/2019
CKD Pharma’s darbepoetin alfa biosimilar launch... Biosimilars/News | Posted 18/01/2019
EMA continues to be open to alternative clinica... Biosimilars/Research | Posted 18/01/2019
Safety of brand-name and generic angiotensin II... Generics/Research | Posted 18/01/2019
Positive phase III results for rituximab biosim... Biosimilars/Research | Posted 18/01/2019
Celltrion wins patent suit in Japan over trastu... Biosimilars/General | Posted 18/01/2019
Medicines for Europe 15th Legal Affairs Conference Conferences | Posted 18/01/2019
Medicines for Europe 17th Biosimilar Medicines... Conferences | Posted 18/01/2019


FDA issues final guidance on liposome drug products Posted 27/04/2018

On 4 April 2018, the US Food and Drug Administration (FDA) issued a new draft...


FDA approves 40 mg follow-on version of glatira... Non‐Biological Complex Drugs/News | Posted 09/03/2018
Mylan launches first follow-on glatiramer aceta... Non‐Biological Complex Drugs/News | Posted 15/02/2018
Biosimilars and follow-on NBCDs for MS in Europ... Non‐Biological Complex Drugs/Research | Posted 19/01/2018
Impax announces FDA approval of follow-on sevel... Non‐Biological Complex Drugs/News | Posted 17/11/2017
FDA approves follow-on version of sevelamer Non‐Biological Complex Drugs/News | Posted 30/06/2017
Challenges in the regulation of NBCDs Non‐Biological Complex Drugs/Research | Posted 12/05/2017
Scientific and regulatory considerations for fo... Non‐Biological Complex Drugs/Research | Posted 05/05/2017
Equivalence of complex drug products Non‐Biological Complex Drugs/Reports | Posted 14/04/2017
Follow-up studies needed to ensure safety for f... Non‐Biological Complex Drugs/Research | Posted 31/03/2017
Warning letter causes delays for follow-on glat... Non‐Biological Complex Drugs/News | Posted 17/03/2017
Is the EU ready for non-biological complex drug... Non‐Biological Complex Drugs/Research | Posted 03/03/2017
Follow-on versions of glatiramer acetate in Rus... Non‐Biological Complex Drugs/News | Posted 24/02/2017
Non-biological complex drugs and pharmacopoeias Non‐Biological Complex Drugs/Research | Posted 10/02/2017
In vitro analysis of follow-on versions of seve... Non‐Biological Complex Drugs/Research | Posted 18/11/2016
Determining the bioequivalence of follow-on iro... Non‐Biological Complex Drugs/Reports | Posted 04/11/2016
FDA to set up abbreviated pathway for complex p... Non‐Biological Complex Drugs/Polices & Legislation | Posted 21/10/2016
Challenges in the assessment of ophthalmic emul... Non‐Biological Complex Drugs/Reports | Posted 07/10/2016
Cancer lab to evaluate bioequivalence of nanosi... Non‐Biological Complex Drugs/News | Posted 23/09/2016
A conference on ‘Equivalence of Complex Drug Pr... Non‐Biological Complex Drugs/News | Posted 09/09/2016
Collaboration to introduce nanotechnologies in... Non‐Biological Complex Drugs/News | Posted 26/08/2016
Iron carbohydrate follow-on NBCDs Non‐Biological Complex Drugs/Reports | Posted 12/08/2016
Rigorous approach used to approve a follow-on v... Non‐Biological Complex Drugs/Research | Posted 29/07/2016
US guidelines for follow-on NBCDs Non‐Biological Complex Drugs/Guidelines | Posted 10/06/2016
Non-biological complex drugs and their follow-o... Non‐Biological Complex Drugs/Research | Posted 03/06/2016
Is a new pathway for NBCDs on the way in the US? Non‐Biological Complex Drugs/Polices & Legislation | Posted 27/05/2016
Follow-on glatiramer acetate gains European app... Non‐Biological Complex Drugs/News | Posted 13/05/2016
FDA includes follow-on versions in its new cycl... Non‐Biological Complex Drugs/Guidelines | Posted 29/04/2016
Switching between originator and follow-on iron... Non‐Biological Complex Drugs/Research | Posted 22/04/2016
Follow-on intravenous iron formulations in haem... Non‐Biological Complex Drugs/Research | Posted 01/04/2016
Glatiramoid follow-on NBCDs Non‐Biological Complex Drugs/Reports | Posted 11/03/2016
FDA includes follow-on versions in its new lipo... Non‐Biological Complex Drugs/Guidelines | Posted 26/02/2016
EU guidelines for follow-on NBCDs Non‐Biological Complex Drugs/Guidelines | Posted 22/01/2016
GDUFA regulatory priorities for 2016 include co... Non‐Biological Complex Drugs/Polices & Legislation | Posted 11/12/2015
Liposomal follow-on NBCDs Non‐Biological Complex Drugs/Reports | Posted 11/12/2015
Regulations for follow-on NBCDs Non‐Biological Complex Drugs/Reports | Posted 13/11/2015
Status and regulatory issues surrounding follow... Non‐Biological Complex Drugs/Reports | Posted 05/11/2015
Follow-on glatiramer acetate (M356) claimed as... Non‐Biological Complex Drugs/Research | Posted 05/11/2015
EMA issues reflection paper for follow-on versi... Non‐Biological Complex Drugs/Guidelines | Posted 05/11/2015
FDA approves first follow-on version of glatira... Non‐Biological Complex Drugs/News | Posted 05/11/2015